OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) shares fell -4.08% in last trading session and ended the day at $2.35. OGXI has a return on assets of -36.90%. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) quarterly performance is -16.07%.
OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) was upgraded by Zacks Investment Research from a “hold”rating to a “strong-buy” rating in a report released on Tuesday, Marketbeat.com reports. The firm currently has a $2.75 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 17.02% from the company’s previous close.
EMC Corporation (NYSE:EMC) caters to the Technology space. It has a net profit margin of 9.60% and weekly performance is -0.32%. On the last day of trading company shares ended up at $25.17. EMC Corporation (NYSE:EMC) distance from 50-day simple moving average (SMA50) is -1.17%.
EMC Corporation (NYSE:EMC) said that it will connect more of its storage systems to public and private clouds via pre-built integrations. The storage giant said its high-end EMC VMAX and VNX systems will connect to public and private clouds. The company also expanded its data protection tools via its Spanning unit and cloud connections.
On 17 November, PDC Energy, Inc. (NASDAQ:PDCE) shares fell -1.80% and was closed at $58.89. PDCE EPS growth in last 5 year was 21.20%. PDC Energy, Inc. (NASDAQ:PDCE) year to date (YTD) performance is 42.69%.
On 5 November, PDC Energy, Inc. (NASDAQ:PDCE) reported its 2015 third quarter financial and operating results. Net cash from operating activities increased 94% to $136.5 million; exceeded capital expenditures of $130.9 million.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) shares advanced 0.89% in last trading session and ended the day at $1.13. PPHM Gross Margin is 46.50% and its has a return on assets of -78.90%. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) quarterly performance is 0.89%.
On 9 November, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma.
Keurig Green Mountain, Inc. (NASDAQ:GMCR) caters to the Consumer Goods space. It has a net profit margin of 11.60% and weekly performance is -19.80%. On the last day of trading company shares ended up at $40.13. Keurig Green Mountain, Inc. (NASDAQ:GMCR) distance from 50-day simple moving average (SMA50) is -5.93%.
On 13 November, Keurig Green Mountain, Inc. (NASDAQ:GMCR) reported a gross profit of $349 million or 36.0% of net sales in its third quarter of fiscal 2015. It fell 750 basis points compared to F3Q14. There was an impact of 190 basis points on gross margin because of a charge on obsolescence of finished goods at $8 million related to Keurig brewers. It fell by 11% compared to the F2Q15.
Leave a Reply